171 related articles for article (PubMed ID: 24164913)
21. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients.
Balci M; Kirkpantur A; Gulbay M; Gurbuz OA
Hemodial Int; 2010 Oct; 14(4):425-32. PubMed ID: 20955275
[TBL] [Abstract][Full Text] [Related]
22. The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients.
Park SY; Jeong KH; Moon JY; Lee SH; Ihm CG; Rhee SY; Woo JT; Oh IH; Lee TW
Clin Exp Nephrol; 2010 Jun; 14(3):239-43. PubMed ID: 20376517
[TBL] [Abstract][Full Text] [Related]
23. The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk.
Masson S; Agabiti N; Vago T; Miceli M; Mayer F; Letizia T; Wienhues-Thelen U; Mureddu GF; Davoli M; Boccanelli A; Latini R;
J Intern Med; 2015 Mar; 277(3):318-330. PubMed ID: 24620922
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular disease and cognitive function in maintenance hemodialysis patients.
Weiner DE; Scott TM; Giang LM; Agganis BT; Sorensen EP; Tighiouart H; Sarnak MJ
Am J Kidney Dis; 2011 Nov; 58(5):773-81. PubMed ID: 21778003
[TBL] [Abstract][Full Text] [Related]
25. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.
Seiler S; Cremers B; Rebling NM; Hornof F; Jeken J; Kersting S; Steimle C; Ege P; Fehrenz M; Rogacev KS; Scheller B; Böhm M; Fliser D; Heine GH
Eur Heart J; 2011 Nov; 32(21):2688-96. PubMed ID: 21733911
[TBL] [Abstract][Full Text] [Related]
26. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients.
Srivaths PR; Goldstein SL; Silverstein DM; Krishnamurthy R; Brewer ED
Pediatr Nephrol; 2011 Jun; 26(6):945-51. PubMed ID: 21359960
[TBL] [Abstract][Full Text] [Related]
27. Lower serum fibroblast growth factor-23 levels may suggest malnutrition in maintenance haemodialysis patients.
Mizuiri S; Nishizawa Y; Yamashita K; Ono K; Oda M; Usui K; Shigemoto K
Nephrology (Carlton); 2014 Sep; 19(9):568-73. PubMed ID: 24947687
[TBL] [Abstract][Full Text] [Related]
28. Clinical predictors of individual cognitive fluctuations in patients undergoing hemodialysis.
Costa AS; Tiffin-Richards FE; Holschbach B; Frank RD; Vassiliadou A; Krüger T; Eitner F; Gross T; Shah NJ; Schulz JB; Floege J; Reetz K
Am J Kidney Dis; 2014 Sep; 64(3):434-42. PubMed ID: 24679895
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.
Hsu HJ; Wu MS
Am J Med Sci; 2009 Feb; 337(2):116-22. PubMed ID: 19214027
[TBL] [Abstract][Full Text] [Related]
30. Frailty and Cognitive Function in Incident Hemodialysis Patients.
McAdams-DeMarco MA; Tan J; Salter ML; Gross A; Meoni LA; Jaar BG; Kao WH; Parekh RS; Segev DL; Sozio SM
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2181-9. PubMed ID: 26573615
[TBL] [Abstract][Full Text] [Related]
31. Cardiac calcifications are more prevalent in children receiving hemodialysis than peritoneal dialysis.
Srivaths P; Krishnamurthy R; Brunner L; Logan B; Bennett M; Ma Q; VanDeVoorde R; Goldstein SL
Clin Nephrol; 2014 Apr; 81(4):231-7. PubMed ID: 24656313
[TBL] [Abstract][Full Text] [Related]
32. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients.
Inaba M; Okuno S; Imanishi Y; Yamada S; Shioi A; Yamakawa T; Ishimura E; Nishizawa Y
Osteoporos Int; 2006 Oct; 17(10):1506-13. PubMed ID: 16896512
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast Growth Factor 23 is Associated With Adiposity in Patients Receiving Hemodialysis: Possible Cross Talk Between Bone and Adipose Tissue.
Chiang JM; Kaysen GA; Schafer AL; Delgado C; Johansen KL
J Ren Nutr; 2018 Jul; 28(4):278-282. PubMed ID: 29606304
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
Isakova T; Xie H; Yang W; Xie D; Anderson AH; Scialla J; Wahl P; Gutiérrez OM; Steigerwalt S; He J; Schwartz S; Lo J; Ojo A; Sondheimer J; Hsu CY; Lash J; Leonard M; Kusek JW; Feldman HI; Wolf M;
JAMA; 2011 Jun; 305(23):2432-9. PubMed ID: 21673295
[TBL] [Abstract][Full Text] [Related]
35. High serum phosphorus and FGF 23 levels are associated with progression of coronary calcifications.
Srivaths PR; Goldstein SL; Krishnamurthy R; Silverstein DM
Pediatr Nephrol; 2014 Jan; 29(1):103-9. PubMed ID: 23921492
[TBL] [Abstract][Full Text] [Related]
36. Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients.
Viaene L; Bammens B; Meijers BK; Vanrenterghem Y; Vanderschueren D; Evenepoel P
Nephrol Dial Transplant; 2012 May; 27(5):2017-22. PubMed ID: 22025115
[TBL] [Abstract][Full Text] [Related]
37. FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients.
Moldovan D; Moldovan I; Rusu C; Kacso I; Patiu IM; Gherman-Caprioara M
Int Urol Nephrol; 2014 Jan; 46(1):121-8. PubMed ID: 23549862
[TBL] [Abstract][Full Text] [Related]
38. Effect of serum FGF-23, MGP and fetuin-A on calcium-phosphate metabolism in maintenance hemodialysis patients.
Xiao DM; Wu Q; Fan WF; Ye XW; Niu JY; Gu Y
Hemodial Int; 2013 Oct; 17(4):483-92. PubMed ID: 23490272
[TBL] [Abstract][Full Text] [Related]
39. FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients.
Turan MN; Kircelli F; Yaprak M; Sisman AR; Gungor O; Bayraktaroglu S; Ozkahya M; Asci G; Floege J; Ok E
Int Urol Nephrol; 2016 Apr; 48(4):609-17. PubMed ID: 26865177
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor-23 and cardiac structure and function.
Agarwal I; Ide N; Ix JH; Kestenbaum B; Lanske B; Schiller NB; Whooley MA; Mukamal KJ
J Am Heart Assoc; 2014 Feb; 3(1):e000584. PubMed ID: 24525546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
